Lumos Pharma, Inc.: Pancreatic Neoplasms trials
The registry lists 10 Pancreatic Neoplasms studies with Lumos Pharma, Inc. as lead sponsor. 0 are open to participants now and 1 have results posted.
Phase 1 4Phase 2 6Phase 3 2No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic CancerCompletedNCT02077881Phase 1/2Results posted
- Long Term Follow-Up Study for Subjects Previously Treated With Algenpantucel-L (HyperAcute-Pancreas) ImmunotherapyTerminatedNCT03165188
- Immunotherapy and SBRT Study in Borderline Resectable Pancreatic CancerTerminatedNCT02405585Phase 2
- Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic CancerTerminatedNCT01836432Phase 3
- Immunotherapy Study for Surgically Resected Pancreatic CancerCompletedNCT01072981Phase 3
- IDO Inhibitor Study for Relapsed or Refractory Solid TumorsTerminatedNCT00739609Phase 1
- Low Dose Vaccine Study for Surgically Resected Pancreatic CancerTerminatedNCT00614601Phase 2
- Vaccine Study for Surgically Resected Pancreatic CancerCompletedNCT00569387Phase 2
- Study of CRLX101 (NLG207) in the Treatment of Advanced Solid TumorsCompletedNCT00333502Phase 1/2
- Vaccine Treatment for Surgically Resected Pancreatic CancerCompletedNCT00255827Phase 1/2